Related Experiment Video
Updated: Aug 11, 2026
Single Molecule Analysis of Laser Localized Psoralen Adducts
Published on: April 20, 2017
Analysis of tamoxifen-DNA adducts in endometrial explants by MS and 32P-postlabeling
Frederick A Beland1, Mona I Churchwell, Alan Hewer
1Division of Biochemical Toxicology, National Center for Toxicological Research, Jefferson, AR 72079, USA. fbeland@nctr.fda.gov
Abstract:
The nonsteroidal antiestrogen tamoxifen increases the risk of endometrial cancer; however, the mechanism for the induction of these tumors is not known. Recently, Sharma et al. [Biochem. Biophys. Res. Commun. 307 (2003) 157], using high performance liquid chromatography (HPLC) with online postcolumn photochemical activation and fluorescence detection, reported the presence of (E)-alpha-(deoxyguanosin- N2-yl)tamoxifen in DNA from human endometrial explants incubated with tamoxifen. Inasmuch as the methodology used by these investigators does not allow unambiguous characterization of tamoxifen-DNA adducts, we have used two additional techniques (HPLC coupled with electrospray ionization tandem mass spectrometry and 32P-postlabeling analyses) to assay for the presence of tamoxifen-DNA adducts in the human endometrial explant DNA. Tamoxifen-DNA adducts were not detected by either method.
Insights
Tamoxifen increases endometrial cancer risk, but the mechanism is unclear. This study found no tamoxifen-DNA adducts in human endometrial cells, questioning a previously reported finding.
Area of Science:
- Oncology
- Molecular Biology
- Toxicology
Background:
- Tamoxifen, a nonsteroidal antiestrogen, is linked to increased endometrial cancer risk.
- The precise mechanism behind tamoxifen-induced endometrial tumors remains unknown.
- Previous research suggested tamoxifen-DNA adduct formation in human endometrial explants.
Discussion:
- This study re-evaluated tamoxifen-DNA adducts in human endometrial explants using advanced techniques.
- High-performance liquid chromatography (HPLC) coupled with electrospray ionization tandem mass spectrometry was employed.
- 32P-postlabeling analyses were also utilized for sensitive adduct detection.
Key Insights:
- Tamoxifen-DNA adducts were not detected in human endometrial explant DNA by either HPLC-MS/MS or 32P-postlabeling.
- These findings challenge the previous report of tamoxifen-DNA adducts using a different methodology.
- The absence of detectable adducts suggests alternative mechanisms for tamoxifen's carcinogenicity.
Outlook:
- Further research is needed to elucidate the exact mechanism of tamoxifen-induced endometrial carcinogenesis.
- Investigating other potential DNA-damaging pathways or cellular responses to tamoxifen is warranted.
- Understanding tamoxifen's molecular actions is crucial for managing its oncogenic risks.
More Related Videos
09:33Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling
Published on: March 20, 2018
07:37An Integrated Raman Spectroscopy and Mass Spectrometry Platform to Study Single-Cell Drug Uptake, Metabolism, and Effects
Published on: January 9, 2020